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Background: BRAF mutations occur in approximately 8% of all human cancers and approach 50% in melanoma
and papillary carcinoma of thyroid. These mutations provide potentially valuable diagnostic, prognostic and
treatment response prediction markers. A sensitive, specific, low-cost assay to detect these mutations is needed.
Results: To detect BRAF V600E mutation in formalin-fixed, paraffin-embedded (FFPE) tissue, we developed a
method using Amplification Refractory Mutation System (ARMS)-PCR. This method was designed to amplify three
products in a single reaction tube: a 200 bp common product serving as an amplification control, a 144 bp BRAF
V600E specific product, and a 97 bp wild-type (wt) specific product. The sensitivity of this method was determined
to be as low as 0.5% for the BRAF V600E allele in a wild-type background. This method was successfully validated in
72 thyroid tumors. It detected V600E mutation in 22 out of 33 (67%) of the conventional papillary thyroid
carcinoma (PTC), 8 out of 12 (75%) of the tall-cell variant of PTC, whereas none of the 10 follicular variant of PTC
showed BRAF V600E mutation. In addition, none of the 14 follicular adenomas and 3 follicular carcinomas had BRAF
V600E mutation. As a comparison method, direct dideoxy sequencing found only 27 out of 30 (90%) mutations
detected by ARMS-PCR method, suggesting that this ARMS-PCR method has higher sensitivity.
Conclusions: Our ARMS-PCR method provides a new tool for rapid detection of BRAF V600E mutation. Our results
indicate that ARMS-PCR is more sensitive than automated dideoxy sequencing in detecting low BRAF V600E allele
burdens in FFPE tumor specimen. The strategy of this ARMS-PCR design may be adapted for early detection of
point mutations of a variety of biomarker genes.Background
BRAF gene encodes a serine/threonine protein kinase that
functions downstream of RAS in the RAS-RAF-MEK-ERK
signaling pathway, also known as mitogen activated pro-
tein kinase (MAPK) pathway, which is important in regu-
lating cellular responses to extracellular signals including
epidermal growth factor (EGF) [1]. Upon activation by
receptor binding, RAS proteins recruit RAF to the cellular
membrane where RAF is phosphorylated [2]. Activated
RAF proteins further phosphorylate MEK1 and MEK2,
which then phosphorylate ERK1 and ERK2. Phosphory-
lated ERK proteins regulate cellular functions through
activation of transcription factors including p53, SMAD4,* Correspondence: huangt@wcmc.com; wenyongzhang@gmail.com
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reproduction in any medium, provided the orELK1, c-Myc and c-Fos [2,3]. Activating mutations in RAS
and BRAF permit constitutive MAPK pathway activation
independent of growth factor stimulation, thereby causing
deregulation in cellular growth and survival. BRAF muta-
tions occur in approximately 8% of all human cancers,
with high mutation frequency in malignant melanoma
(50-70%), classic papillary carcinoma of the thyroid
(40-70%), colorectal cancer (CRC, 5-15%), ovarian cancer
and hairy cell leukemia (5-100%) [4,5]. A T1799A trans-
version resulting in valine-to-glutamate substitution at
codon 600 (V600E) accounts for over 80% of all BRAF
mutations [6,7], and almost all mutations in thyroid
tumors [8].
Molecular testing for BRAF mutation can provide
valuable diagnostic information, treatment selection, and
may help predict prognosis. Like KRAS mutations, CRC
patients with activating BRAF mutations do not respondLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[9,10]. Because BRAF mutations occur in 5-15% of CRC
and are usually mutually exclusive with KRAS mutations
[11], a substantial number of these CRC patients may
benefit from BRAF mutation testing before initiating
MoAb treatment [9]. In thyroid, BRAF V600E mutation
is restricted to malignant tumors, and is associated with
papillary thyroid cancer (PTC), and PTC-derived poorly-
differentiated and anaplastic carcinoma [7,8]. Therefore,
BRAF mutation testing can be helpful as an adjunct
method to improve diagnostic accuracy in difficult cases,
such as thyroid FNA samples with indeterminate and
atypical cytology [12,13].
There are several methods for BRAF V600E mutation
testing, including dideoxy sequencing, colorimetric
Mutector assay, allele-specific real-time PCR, pyrose-
quencing, high resolution melting (HRM) analysis and
COLD-PCR [14-17]. These methods vary in their sensi-
tivity, assay complexity and costs. Automated dideoxy
sequencing is considered the “gold standard” method for
mutation testing. However, it is limited by relatively
complex procedure, overall high costs and low analytical
sensitivity of detecting approximately 15-20% mutant
allele in a wild-type background [18]. ARMS-PCR is a
highly sensitive, specific and low-cost mutation detection
method with reported analytical sensitivity ranging from
0.1% to 2% for JAK2 V617F mutation detection [19,20].
Here we report the development of a highly sensitive
and specific ARMS-PCR assay to detect BRAF V600E
mutation in formalin-fixed, paraffin-embedded (FFPE)
tissue with sensitivity as low as 0.5%. We successfully
used this assay to characterize the frequency of BRAF
V600E in thyroid tumors.
Methods
Sample source
Cell lines HT-29 (heterozygous for BRAF V600E) and K-
562 (wt BRAF without V600E mutation) were cultured
in RPMI1640 supplemented with 10% fetal calf serum.
Anonymized FFPE thyroid tumor tissue blocks were
obtained from the Department of Pathology for clinical
protocol development.
DNA extraction
3–5 sections of FFPE tissues (5 micron/section) were
deparaffinized by xylene and ethanol treatment, and
digested with proteinase K at 56°C overnight. Genomic
DNA was extracted using ZR genomic DNA I kit
(ZYMO Research Corp., Orange, CA) as recommen-
ded. DNA extraction from culture cells was other-
wise the same as above except no deparaffinization
was performed. DNA was then qualified/quantified
with ND-1000 spectrophotometer (NanoDrop Products,
Wilmington, DE).ARMS-PCR and sequencing
The ARMS-PCR primer sequences were forward (Fo):
5 -CTCTTCATAATGCTTGCTCTGATAG-3′; reverse
(Ro): 5′-GCCTCAATTCTTACCATCCAC-3′; forward
wild-type identifying (Fiwt): 5′-GTGATTTTGGTCT
AGCTACAGT-3′ and reverse mutation identifying
(Rimut):5′-CCCACTCCATCGAGATTTCT-3′. PCR was
performed in a 25 μl final volume containing 1 × Buffer,
2 mM MgCl2, 1 unit of Hotstar Taq DNA polymerase
(Qiagen Science, Valencia, CA), 200 μM each dNTP, 400
nM primer Fo, 200 nM primer Ro and Fiwt, 800 nM pri-
mer Rimut and 30 ng genomic DNA template. PCR ampli-
fication was carried out by denaturation at 95°C for 5 min,
followed by 40 cycles of 94°C for 20 sec, 68°C for 20 sec
and 72°C for 20 sec with a final extension at 72°C for
5 min. PCR products were analyzed by 2% agarose gel elec-
trophoresis. Automated dideoxy sequencing was performed
by Macrogen USA (Rockville, MD) after PCR amplification
using the Fo-Ro primer pair and the ampliocons purifica-
tion using QIAquick PCR purification kit (Qiagen).
Assay sensitivity study
HT-29 cell DNA with heterozygous BRAF V600E muta-
tion was serial diluted with DNA from a wt BRAF cell
line K-562, to generate a sensitivity panel consisting of 0,
0.1%, 0.25%, 0.5%, 1%, 2.5%, 5%, 10%, 20% and 50% of
BRAF V600E allele in a wild-type background. The PCR
was performed under the optimized condition as above.
Results
Method establishment
The BRAF V600E ARMS-PCR assay contains 4 primers
in a single PCR reaction tube with the two outside pri-
mers designed to amplify a common fragment of 200 bp
flanking the mutation site which can serve as an internal
amplification control (Figure 1A). The two internal pri-
mers are either specific for the mutant sequence or the
wild-type sequence. The mutant and wild-type sequences
are distinguishable by the difference of fragment size, as
the amplified wild-type fragment is 97 bp, while the mu-
tant fragment is 144 bp. The concentrations of PCR pri-
mers and magnesium, the annealing temperature and
other cycling parameters were determined by multiple ex-
ploring studies, and the condition given here is the final
optimized one.
Assay sensitivity
To assess the analytical sensitivity of the assay, BRAF
V600E mutation containing DNA was spiked into wild-
type BRAF DNA, the PCR was performed and showed
that the assay we used could detect as low as, if not bet-
ter than, 0.5% BRAF V600E allele in the background of
wild-type DNA (Figure 1B). Therefore, the analytical
sensitivity of the assay is 0.5%.
Figure 1 BRAF V600E ARMS-PCR. A, Four PCR primers are included in one PCR tube. Fo-Ro primer pair generates a common fragment of
200 bp flanking the mutation site. Fo-Rimut primer pair generates the 144 bp fragment specific to BRAF V600E. Fiwt-Ro primer pair generates a
97 bp fragment specific to wild-type BRAF. B, Sensitivity study. Agarose gel electrophoresis showed band pattern of a mixing study using BRAF
V600E positive HT-29 cell DNA spiked into K-562 cell DNA at wide range of ratio namely 0, 0.1%, 0.25%, 0.5%, 1%, 2.5%, 5%, 10%, 20% and 50%.
The assay can detect 0.5% BRAF V600E allele in a wild-type background. M, 100 bp DNA marker; BK, blank (no DNA) control.
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sequencing using thyroid tumor specimens
We then analyzed BRAF V600E in thyroid tumors using
the ARMS-PCR method. A total of 72 thyroid tumors
were tested, including 55 PTCs and 17 follicular tumors.
Among 55 PTCs, 33 were conventional type, 12 were
tall-cell variant, and 10 were follicular variant (Table 1).
ARMS-PCR results showed that 22 out of 33 (67%) of
the conventional PTC, 8 out of 12 (75%) of the tall-cell
variant of PTC, and none of the 10 follicular variant of
PTC harbored BRAF V600E mutation. Interestingly,
none of the 14 follicular adenomas and 3 follicular car-
cinomas showed BRAF V600E mutation.
As a comparison, automated dideoxy sequencing was
used to analyze 42 tumors including all 30 BRAF V600E
positive tumors and 12 of the BRAF V600E negative
tumors from ARMS-PCR assayed samples. Among the
30 BRAF V600E positive tumors detected with ARMS-
PCR assay, direct sequencing identified the mutation in
27 tumors, but failed to identify 3 tumors that had BRAF
V600E mutation, possibly due to the lower sensitivity of
detection of automated dideoxy sequencing. Figure 2A
depicts the representative ARMS-PCR results, showing





Papillary Thyroid Carcinoma 55 30 55
Conventional Type 33 22 67
Tall-cell Variant 12 8 75
Follicular Variant 10 0 0
Follicular Tumor 17 0 0
Follicular Adenoma 14 0 0
Follicular Carcinoma 3 0 0V600E bands (144 bp). This is comparable to the mutant
band intensity of the 2.5% V600E allele burden positive
control included in the study. Figure 2B depicts the rep-
resentative sequencing result for sample 9, showing the
mutant signal was below the detection limit of the assay.
While ARMS-PCR for sample 13 showed a strong
V600E mutant band, and direct sequencing showed A/T
double peaks with approximately equal height (Figure 2C).
Histologic study of specimen 9 showed that the tumor
constituted only a small fraction of the tissue area and
sample 13 had a high tumor percentage (Figure 2D).
These two cases illustrate the importance of high assay
sensitivity of our ARMS-PCR assay to detect low BRAF
V600E allele burdens in tumor samples. The assay results
for the 12 BRAF V600E negative tumors were concordant
between the ARMS-PCR and direct sequencing. All 14
cases of follicular adenomas had no mutated band
detected by ARMS-PCR, showing the specificity of our
assay was 100% in this validation study.
Overall, our results indicate that ARMS-PCR is more
sensitive than automated dideoxy sequencing in detect-
ing low BRAF V600E allele burdens in FFPE tumor
specimen.
Discussion
For the development and implementation of persona-
lized medicine, a sensitive, specific, low-cost and easy-
to-implement assay to identify various genetic alterations
such as BRAF V600E mutation is needed. By selecting
primer pair and optimizing PCR cycling conditions, we
achieved this goal by using ARMS based PCR. One of
the advantages of ARMS-PCR is that the assay is
designed to amplify a relative larger common fragment
of DNA that flanks the mutation site in all samples re-
gardless of their mutation status. This common frag-
ment conveniently serves as an internal control for










Specimen 9 Specimen 13
Tumor Area 15%          50%
Figure 2 A, Representative BRAF V600E ARMS-PCR results. Specimen 9, 26 and 32 had a low abundance of BRAF V600E mutation with band
intensity similar to that of the 2.5% sensitivity control. Specimen 13 was strongly positive for BRAF V600E mutation. B, Direct dideoxy sequencing
of specimen 9 failed to identify BRAF V600E mutation as the mutant allele burden was below the limit of detection. C, Direct dideoxy sequencing
of specimens 13 showed that the mutant allele (A) was more abundant than the wild-type allele (T). D, H&E stain of specimens 9 and 13 showed
that tumor areas accounted for ~15% and 50% of the total specimen areas, respectively.
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ition. The mutant or wild-type specific PCR amplifica-
tions take place in the same reaction tube, thereby
allowing the mutant or wild-type specific PCR primers
to compete for binding to very limited templates. To in-
crease the sensitivity for detecting this mutation, we
tried to change the ratio of four primers and found that
the combination of 400 nM primer Fo, 200 nM primer
Ro and Fiwt, 800 nM primer Rimut resulted the stron-
gest mutant band. The primer binding to template varies
based on their annealing conditions, but relative high Fo
and the highest Rimut primer concentrations might
favor the production of mutant product in our design. In
addition, relative low concentration for Fiwt and Ro pri-
mers might reduce full length and wild type productformation by the competition effect of each primer. By
such a design, the three products were produced at rea-
sonably comparable levels. Otherwise, the wild type or
whole length bands might overshadow the weak mutant
band if the mutant BRAF V600E abundance is low,
which is frequently the case for clinical specimens. With
this study, we improved assay sensitivity to as low as
0.5% mutant allele level in the background of wild-type
DNA, which is quite sensitive among ARMS-PCR meth-
ods [21]. This sensitivity is very difficult to reach with
direct dideoxy sequencing which has the sensitivity of
15-20%, and with pyrosequencing which has greatly
increased sensitivity to about 2% [22,23]. Considering
DNA samples obtained from FFPE tissue is often frag-
mented due to damage by formalin fixation, we designed
Huang et al. Biomarker Research 2013, 1:3 Page 5 of 6
http://www.biomarkerres.org/content/1/1/3our PCR product size to be small (no more than 200 bp)
to maximize the chance of successful amplification. This
was proven to be helpful since all 72 FFPE samples had
successful amplification.
The reported prevalence of BRAF V600E mutation for
conventional PTC varied from 36% to 67% in the US and
European studies [7,8,24-27], and was 83% in a Korean
study [28]. The difference in prevalence could be due to
different study population or different methodologies
used. The prevalence of BRAF V600E mutation in the tall-
cell variant PTC is in general higher than that of the con-
ventional type, with a mean prevalence of 77% in several
studies [8]. On the contrary, the follicular variant of PTC
is rarely involved by BRAF V600E mutation, with a mean
prevalence of 12% [8]. Using ARMS-PCR, we tested 72
thyroid tumors and determined that the frequencies of
BRAF V600E mutation in the conventional, tall-cell and
follicular variants of PTC were 66%, 75% and 0%, respect-
ively. Our frequency of BRAF V600E mutation in conven-
tional PTC was at the high end of the reported results,
possibly reflecting our improved assay sensitivity com-
pared with automated DNA sequencing, which was the
method used in many of the reported studies. Our study
showed that DNA sequencing method missed 3 out of 30
PTC samples with BRAF V600E detected by ARMS-PCR,
resulting in a false negative rate of 10%. In our validation
study, the assay specificity is 100% (14/14) based on nega-
tive mutation in follicular adenoma. This is consistent
with previous reports since benign follicular adenoma has
not been found to harbor the BRAF mutation [8].
BRAF V600E mutation testing has demonstrated util-
ity in helping select CRC patients who are considering
monoclonal antibody therapy as wild-type BRAF is
required for response to anti-EGFR antibodies [9] and
improve diagnostic accuracy in thyroid FNA samples
[12,13]. In addition, BRAF V600E mutation is associated
with sporadic microsatellite instable CRC, but not her-
editary non-polyposis colorectal cancer (HNPCC) syn-
drome [29,30]. Therefore, the presence of BRAF V600E
mutation is an exclusion criteria for HNPCC genetic
testing [29,30]. BRAF V600E mutation testing can also
help facilitate clinical studies of BRAF-targeted therapies
[31]. The improved understanding of the role BRAF
mutations in cancer diagnosis, prognosis and treatment
has increased the need for BRAF mutation testing [4,32].
New methods are constantly being developed for
BRAF V600E mutation detection. Shifted termination
assay (STA) developed by TrimGen Corporation
declared the sensitivity of 1-5% [33]. Lang et al. devel-
oped an allele-specific, also known as ARMS, real-time
PCR using Taqman probe to increase the sensitivity to
1% and using internal control to exclude false negative
results [34]. Morandi et al. developed an allele specific
locked nucleic acid (LNA) quantitative PCR assay usingLNA-modified allele specific primers and LNA-modified
beacon probes to achieve sensitivity of 0.1% [35]. Dual-
priming oligonucleotide (DPO)-based multiplex PCR
was commercially available from Seegene (Seoul, Korea)
and has a sensitivity of 2% [36]. Qiagen developed a
BRAF mutation detection PCR kit with a sensitivity of
1.27%. Our method using ARMS-PCR therefore appears
to have high sensitivity (0.5%) for BRAF V600E mutation
detection.
Conclusions
We have developed a sensitive, specific and low-cost
ARMS-PCR assay to detect BRAF V600E mutation.
Comparative study showed that this assay is superior to
automated dideoxy sequencing in terms of assay sensi-
tivity, turn-around time and costs. The ARMS-PCR
assay can be easily implemented by many molecular la-
boratories for BRAF V600E mutation testing. Our
method provides one of the most sensitive methods for
BRAF V600E gene mutation detection. The principal of
our study design can be potentially adapted to detect
other low abundance point mutations such as tumors
with rich background stroma and post-treatment tumor
samples.
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